Maria Dêbiec‐Rychter

19.5k total citations · 1 hit paper
318 papers, 12.3k citations indexed

About

Maria Dêbiec‐Rychter is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology and Surgery. According to data from OpenAlex, Maria Dêbiec‐Rychter has authored 318 papers receiving a total of 12.3k indexed citations (citations by other indexed papers that have themselves been cited), including 201 papers in Pulmonary and Respiratory Medicine, 111 papers in Gastroenterology and 76 papers in Surgery. Recurrent topics in Maria Dêbiec‐Rychter's work include Sarcoma Diagnosis and Treatment (155 papers), Gastrointestinal Tumor Research and Treatment (111 papers) and Gastric Cancer Management and Outcomes (46 papers). Maria Dêbiec‐Rychter is often cited by papers focused on Sarcoma Diagnosis and Treatment (155 papers), Gastrointestinal Tumor Research and Treatment (111 papers) and Gastric Cancer Management and Outcomes (46 papers). Maria Dêbiec‐Rychter collaborates with scholars based in Belgium, United States and Poland. Maria Dêbiec‐Rychter's co-authors include Raf Sciot, Patrick Schöffski, Agnieszka Woźniak, Anne Hagemeijer, Michel Stul, A. van Oosterom, Piotr Rutkowski, Bartosz Wasąg, M. van Glabbeke and Peter Marynen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Maria Dêbiec‐Rychter

311 papers receiving 12.0k citations

Hit Papers

KIT mutations and dose se... 2006 2026 2012 2019 2006 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    2006 654 citations Maria Dêbiec‐Rychter, Raf Sciot et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maria Dêbiec‐Rychter Belgium 59 7.5k 4.2k 2.7k 2.5k 2.4k 318 12.3k
Jonathan A. Fletcher United States 57 5.6k 0.7× 2.5k 0.6× 1.7k 0.6× 1.8k 0.7× 2.4k 1.0× 129 9.5k
Jonathan C. Trent United States 48 5.1k 0.7× 3.5k 0.8× 2.5k 0.9× 2.2k 0.9× 1.3k 0.6× 283 8.2k
A. van Oosterom Belgium 34 4.2k 0.6× 3.1k 0.7× 1.8k 0.7× 1.7k 0.7× 861 0.4× 88 6.7k
Sandra Silberman United States 15 4.0k 0.5× 3.5k 0.8× 1.8k 0.7× 1.8k 0.7× 1.0k 0.4× 38 6.8k
Agnieszka Woźniak Belgium 38 3.4k 0.5× 2.0k 0.5× 1.6k 0.6× 1.2k 0.5× 1.1k 0.4× 188 5.2k
Philippe A. Cassier France 43 3.2k 0.4× 801 0.2× 4.0k 1.5× 1.1k 0.5× 1.4k 0.6× 295 7.4k
Martin E. Blackstein Canada 37 3.9k 0.5× 2.5k 0.6× 2.0k 0.7× 1.6k 0.6× 1.0k 0.4× 101 6.3k
Sant P. Chawla United States 50 5.4k 0.7× 300 0.1× 3.9k 1.5× 1.4k 0.6× 1.9k 0.8× 300 9.7k
Patrick Pauwels Belgium 60 3.2k 0.4× 480 0.1× 4.2k 1.6× 925 0.4× 4.3k 1.8× 305 10.6k
Giuseppe Zamboni Italy 62 2.7k 0.4× 354 0.1× 7.6k 2.9× 5.4k 2.2× 2.1k 0.9× 289 12.8k

Countries citing papers authored by Maria Dêbiec‐Rychter

Since Specialization
Citations

This map shows the geographic impact of Maria Dêbiec‐Rychter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Dêbiec‐Rychter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Dêbiec‐Rychter more than expected).

Fields of papers citing papers by Maria Dêbiec‐Rychter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Dêbiec‐Rychter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Dêbiec‐Rychter. The network helps show where Maria Dêbiec‐Rychter may publish in the future.

Co-authorship network of co-authors of Maria Dêbiec‐Rychter

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Dêbiec‐Rychter. A scholar is included among the top collaborators of Maria Dêbiec‐Rychter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Dêbiec‐Rychter. Maria Dêbiec‐Rychter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kowalik, Artur, Monika Jurkowska, Ewa Mierzejewska, et al.. (2020). The prognostic role of BRAF and WNT pathways activation in kinase inhibitors-naïve clinical stage III cutaneous melanoma. Melanoma Research. 30(4). 348–357. 2 indexed citations
2.
Arbajian, Elsa, Florian Puls, Cristina R. Antonescu, et al.. (2017). In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets. Clinical Cancer Research. 23(23). 7426–7434. 65 indexed citations
3.
Cornillie, Jasmien, Agnieszka Woźniak, Péter Pokreisz, et al.. (2017). In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models. Molecular Cancer Therapeutics. 16(8). 1566–1575. 16 indexed citations
4.
Cai, Qing, Paola Bonfanti, Kim Vanuytsel, et al.. (2014). Prospectively Isolated NGN3-Expressing Progenitors From Human Embryonic Stem Cells Give Rise to Pancreatic Endocrine Cells. Stem Cells Translational Medicine. 3(4). 489–499. 24 indexed citations
5.
Boichuk, Sergei, Kathleen R. Makielski, Agnieszka Woźniak, et al.. (2014). Unbiased Compound Screening Identifies Unexpected Drug Sensitivities and Novel Treatment Options for Gastrointestinal Stromal Tumors. Cancer Research. 74(4). 1200–1213. 37 indexed citations
6.
Woźniak, Agnieszka, Piotr Rutkowski, Patrick Schöffski, et al.. (2014). Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. Clinical Cancer Research. 20(23). 6105–6116. 121 indexed citations
7.
Looy, Thomas Van, Agnieszka Woźniak, Giuseppe Floris, et al.. (2014). Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy. Clinical Cancer Research. 20(23). 6071–6082. 42 indexed citations
8.
Boichuk, Sergei, Joshua A. Parry, Kathleen R. Makielski, et al.. (2013). The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis. Cancer Research. 73(16). 5120–5129. 77 indexed citations
9.
Jin, Yuesheng, Emely Möller, Karolin H. Nord, et al.. (2012). Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes. Genes Chromosomes and Cancer. 51(5). 510–520. 109 indexed citations
10.
Floris, Giuseppe, Agnieszka Woźniak, Raf Sciot, et al.. (2012). A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal. Clinical Cancer Research. 19(3). 620–630. 59 indexed citations
11.
Lee, Chi‐Hang, Adrián Mariño‐Enríquez, Matt van de Rijn, et al.. (2011). The Histologic Features of Endometrial Stromal Sarcomas Characterized by YWHAE Rearrangement - Distinction from Usual Low-Grade Endometrial Stromal Sarcoma with JAZF1 Rearrangement. Laboratory Investigation. 24. 2 indexed citations
12.
Floris, Giuseppe, Maria Dêbiec‐Rychter, Agnieszka Woźniak, et al.. (2011). The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors. Molecular Cancer Therapeutics. 10(10). 1897–1908. 37 indexed citations
13.
Floris, Giuseppe, Raf Sciot, Agnieszka Woźniak, et al.. (2011). The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous KIT Mutations. Clinical Cancer Research. 17(17). 5604–5614. 41 indexed citations
14.
Lagarde, Pauline, Gaëlle Pérot, Audrey Kauffmann, et al.. (2011). Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors. Clinical Cancer Research. 18(3). 826–838. 102 indexed citations
15.
Woźniak, Agnieszka, Piotr Rutkowski, Raf Sciot, et al.. (2010). Genomic profiling discloses differences in imatinib-resistant gastrointestinal stromal tumors (GIST) with primary KIT exon 9 or KIT exon 11 mutations. 1 indexed citations
16.
Dewaele, Barbara, Giuseppe Floris, Christopher Fletcher, et al.. (2010). Coactivated Platelet-Derived Growth Factor Receptor α and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma. Cancer Research. 70(18). 7304–7314. 68 indexed citations
17.
Floris, Giuseppe, Maria Dêbiec‐Rychter, Raf Sciot, et al.. (2009). Abstract #4692: Efficacy of IPI-504 \#8220;a novel inhibitor of heat shock protein 90\#8221; in a preclinical mouse model of gastrointestinal stromal tumor (GIST). Cancer Research. 69. 4692–4692. 1 indexed citations
18.
Floris, Giuseppe, Maria Dêbiec‐Rychter, Raf Sciot, et al.. (2009). High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model. Clinical Cancer Research. 15(12). 4066–4076. 49 indexed citations
19.
Gasparotto, Daniela, Sabrina Rossi, Italo Bearzi, et al.. (2008). Multiple Primary Sporadic Gastrointestinal Stromal Tumors in the Adult: An Underestimated Entity. Clinical Cancer Research. 14(18). 5715–5721. 57 indexed citations
20.
Personeni, Nicola, Steffen Fieuws, Hubert Piessevaux, et al.. (2008). Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study. Clinical Cancer Research. 14(18). 5869–5876. 129 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan A. Fletcher Breakdown of academic impact, for papers by Jonathan C. Trent Breakdown of academic impact, for papers by A. van Oosterom Breakdown of academic impact, for papers by Sandra Silberman Breakdown of academic impact, for papers by Agnieszka Woźniak Breakdown of academic impact, for papers by Philippe A. Cassier Breakdown of academic impact, for papers by Martin E. Blackstein Breakdown of academic impact, for papers by Sant P. Chawla Breakdown of academic impact, for papers by Patrick Pauwels Breakdown of academic impact, for papers by Giuseppe Zamboni
Rankless by CCL
2026